To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
NCT ID: NCT07143929
Last Updated: 2025-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2025-08-18
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
NCT05059912
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
NCT05979792
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
NCT04934774
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
NCT05149391
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
NCT07280494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anti CD7 CAR-T cells
eligible patients will be treated with CD7-targeted CAR-T cells
CAR-T
autologous CD7-targeted CAR-T cells, single injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAR-T
autologous CD7-targeted CAR-T cells, single injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. According to the clinical practice guidelines for T-cell lymphoma of the National Comprehensive Cancer Network (NCCN) (2022. v2), diagnosis of peripheral T-cell lymphoma；
3. Relapse or refractory peripheral T-cell lymphoma, which has not achieved remission or relapsed after receiving ≥ 1 line of systemic treatment in the past；
4. Histologically confirmed as CD7 positive；
5. According to Lugano2014 standard, enhanced CT before enrollment should indicate at least one evaluable tumor lesion, and PET/CT should show metabolic activity.
6. Blood routine neutrophil count ≥ 1.0×109/L during screening; For individuals without bone marrow invasion, platelet count ≥ 75×109/L, Hb≥80g/L; For individuals with bone marrow invasion, platelet count ≥50×109/L, Hb≥60g/L；
7. Creatinine clearance rate\>60ml/min (Cockcroft and Gault formula); serum total bilirubin≤1.5 times the upper limit of normal value, and serum ALT and AST ≤ 3 times the upper limit of normal value range;
8. left ventricular Ejection fraction (LVEF) ≥ 50%.
9. Estimated survival time of over 3 months.
10. ECOG: 0-1.
11. Subjects or their Legal guardian voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria
2. Primary central nervous system cell lymphoma, or with active central nervous system invasion；
3. If anti-tumor treatment has been received before infusion, and drugs have not been completely eliminated must be excluded;
4. Individuals with a history of allergies to any component in cellular products.
5. Cardiac function:cardiac dysfunction classified as Class III or IV；Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart disease clinically within 12 months of enrollment；The electrocardiogram indicates that the QT interval is significantly prolonged, and the patient has serious heart disease such as serious arrhythmia in the past.
6. Previous history of craniocerebral trauma, Disorders of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.
7. Uncontrolled severe active infections.
8. The subject has a history of other primary cancers, except for the following.
9. Subjects with autoimmune diseases requiring treatment or subjects requiring Immunosuppressive drug treatment.
10. Individuals with graft versus host disease (GvHD) and/or requiring immunosuppressive therapy.
11. Live vaccination within 4 weeks prior to screening.
12. The subject has a history of alcoholism, drug abuse, or mental illness.
13. Individuals with EBV DNA copy numbers greater than the upper limit of normal or positive for EBER; CMV copies greater than the upper limit of normal values; HBV or HCV DNA copy number\>the upper limit of normal value, and active syphilis or AIDS and other virus infected persons.
14. Subjects who were receiving systemic hormone treatment before screening and who were judged by the investigator to need long-term use of systemic hormone during treatment (except for inhalation or local use).
15. Individuals who have participated in other clinical trials within the first 4 weeks of screening.
16. Pregnant and lactating women and subjects with Fertility who cannot take effective contraceptive measures (both men and women).
17. Any situation that the researcher believes may increase the risk of the subject or interfere with the test results.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Anti CD7 CAR-T for r/r PTCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.